Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $27.3 million.

  • Aytu Biopharma's Other Non-Current Liabilities rose 32807.7% to $27.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $27.3 million, marking a year-over-year increase of 32807.7%. This contributed to the annual value of $26.3 million for FY2025, which is 10662.22% up from last year.
  • Aytu Biopharma's Other Non-Current Liabilities amounted to $27.3 million in Q4 2025, which was up 32807.7% from $20.4 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Other Non-Current Liabilities peaked at $27.3 million during Q4 2025, and registered a low of $4.9 million during Q1 2025.
  • Its 5-year average for Other Non-Current Liabilities is $12.3 million, with a median of $9.6 million in 2022.
  • As far as peak fluctuations go, Aytu Biopharma's Other Non-Current Liabilities crashed by 6705.98% in 2022, and later skyrocketed by 32807.7% in 2025.
  • Aytu Biopharma's Other Non-Current Liabilities (Quarter) stood at $8.3 million in 2021, then grew by 17.89% to $9.8 million in 2022, then soared by 31.76% to $12.9 million in 2023, then tumbled by 50.45% to $6.4 million in 2024, then soared by 328.08% to $27.3 million in 2025.
  • Its Other Non-Current Liabilities was $27.3 million in Q4 2025, compared to $20.4 million in Q3 2025 and $26.3 million in Q2 2025.